Insurance
Max Financial Services is a prominent Life Insurance company in India, traded under the stock ticker MFSL.
With a substantial market capitalization of Rs. 35,774.6 Crores, the company operates primarily through its subsidiary, providing business investment and management advisory services alongside its life insurance offerings.
The organization segments its operations into Business Investments and Others, and Life Insurance. It offers a range of products, including participating and nonparticipating linked products that cover life insurance, pension, and health benefits, which also incorporate rider options for both individual and group policies. The distribution of these products is facilitated through various channels such as individual agents, corporate agents, banks, brokers, and others.
Incorporated in 1988 and based in Noida, India, Max Financial Services reported a trailing 12 months revenue of Rs. 49,004 Crores and has experienced an impressive revenue growth of 53.2% over the last three years.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Size: Market Cap wise it is among the top 20% companies of india.
Balance Sheet: Company does NOT have a very strong balance sheet.
Insider Trading: Significant insider selling noticed recently.
Dividend: Stock hasn't been paying any dividend.
Comprehensive comparison against sector averages
MFSL metrics compared to Insurance
Category | MFSL | Insurance |
---|---|---|
PE | 138.74 | 15.42 |
PS | 0.89 | 2.36 |
Growth | 17.6 % | 11.8 % |
MFSL vs Insurance (2021 - 2025)
Summary of Max Financial Services's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Last updated: Feb 25
Management Outlook and Key Points:
1. Strategic Rebranding & Expansion:
2. Growth Metrics:
3. Product Mix & Margins:
4. Operational Efficiency & Digitization:
5. Customer-Centricity:
6. Financials & Solvency:
7. Regulatory & Listing Plans:
8. Medium-Term Focus:
Challenges: Surrender value norms, equity market volatility, and margin pressures near-term. Management remains confident in long-term profitability.
Last updated: Feb 25
Question 1: Shreya Shivani (CLSA)
Could you elaborate on the drivers of the VNB margin decline from 25.3% in 9M FY24 to 21.9% in 9M FY25? What caused the slowdown in the Banca channel, and how might the Insurance Amendment Bill impact Axis Max Life's listing timeline?
Answer: The 400 bps VNB margin decline included ~100 bps from surrender regulations and ~300 bps from ULIP-heavy product mix. Banca's Q3 slowdown was temporary, with growth rebounding in Q4. The Insurance Amendment Bill could shorten regulatory approval for listing, but NCLT processes may still take ~1 year.
Question 2: Avinash (Emkay)
Is the elevated ULIP mix (44% vs. 35% YoY) a strategic shift? How does the rider attachment rate impact margins, and can the Axis Max Life merger proceed if Section 35 amendments are delayed?
Answer: ULIP mix reflects customer demand but will stabilize at 35"“40%. Rider attachment (45% vs. 32% YoY) offsets margin pressure. The merger hinges on Section 35 amendments; no alternatives are being explored.
Question 3: Supratim Datta (Ambit)
Can Q4 sales growth meet the 20% FY25 target given Q3's 16% growth? How might SEBI's proposed mutual fund-term plan hybrid affect ULIPs, and how does Axis Max Life's rebranding impact Tier-2/3 penetration?
Answer: Q4's larger base may lower growth to ~11%, but full-year growth will align with targets. SEBI's hybrid product may complement, not threaten, ULIPs. Rebranding has boosted Tier-2/3 awareness, with ~50% policies from these regions.
Question 4: Manas (Bernstein)
Was Q3's sequential APE decline due to Q2 preponement? Can the Axis brand improve pricing power?
Answer: ~Rs.20"“30 crore of Q2 sales were preponed, but Q3's dip reflected broader industry slowdown. Enhanced brand equity may improve pricing long-term but has no immediate impact.
Question 5: Prayesh Jain (Motilal Oswal)
How did non-PAR mix changes affect margins, and how are commissions adjusted post-surrender regulations? What is ULIP's January 2025 trajectory?
Answer: Stable non-PAR share would have lifted margins. Distributor negotiations balanced upfront/deferred commission cuts. ULIP demand remains resilient despite market corrections.
Question 6: Sanketh Godha (Avendus Spark)
How did rider growth mitigate surrender impacts, and why did non-ULIP segments slow?
Answer: Riders contributed to limiting surrender impact to 100 bps. Non-ULIP slowdown mirrored industry trends; growth prioritized ULIPs to retain market share.
Question 7: Gaurav Nigam (Tunga Investments)
How was surrender impact quantified, and were commissions clawed back?
Answer: Impact derived actuarially from revised surrender values, assuming stable lapse behavior. Commission adjustments varied by partner, with clawbacks/upfront cuts deployed.
Question 8: Gaurav Jain (ICICI Prudential MF)
What is Axis Bank's stake update, and how do tax regime shifts affect demand?
Answer: Axis holds 19.02%, awaiting approvals for 19.99%. Tax changes have minimal impact as 80C is no longer a primary purchase driver.
Question 9: Madhukar Ladha (Nuvama)
What are medium-term growth targets, and why did ULIPs strain profits?
Answer: Prioritizing proprietary/Banca growth. ULIP strain (up 57% YoY) stemmed from higher sales and surrender rules. Economic variance dipped due to equity market corrections.
Understand Max Financial Services ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
Shareholder Name | Holding % |
---|---|
MITSUI SUMITOMO INSURANCE COMPANY LIMITED | 21.86% |
HDFC MUTUAL FUND - HDFC NIFTY LARGE MIDC AP 250 INDEX FUND | 9.02% |
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA NIFTY MIDCAP 150 INDEX FUND | 5.96% |
ICICI PRUDENTIAL NIFTY FINANCIAL SERVICES EX-BANK ETF | 5.9% |
DSP MULTICAP FUND | 4.02% |
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK NIFTY MIDCAP 150 INDEX FUND | 2.76% |
ADITYA BIRLA SUN LIFE TRUSTEE P LTD A/C - ADITYA BIRLA SUN LIFE MULTI ASSET ALLOCATION FUND | 2.75% |
HDFC LIFE INSURANCE COMPANYLIMITED -SHAREHOLDERS SOLVENCY MARGIN ACCOUNT | 2.31% |
MAX VENTURES INVESTMENT HOLDINGS PRIVATE LIMITED | 1.62% |
SMALLCAP WORLD FUND, INC | 1.58% |
MIRAE ASSET NIFTY LARGEMIDCAP 250 INDEX FUND | 1.58% |
KOTAK FUNDS - INDIA MIDCAP FUND | 1.07% |
KUWAIT INVESTMENT AUTHORITY FUND F238 | 1.03% |
POLAR CAPITAL FUNDS PLC - EMERGING MARKET STARS FUND | 1.02% |
Trusts | 0.54% |
NEELU ANALJIT SINGH | 0.03% |
TARA SINGH VACHANI | 0.03% |
ANALJIT SINGH | 0.03% |
PIYA SINGH | 0.03% |
VEER SINGH | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Analysis of Max Financial Services's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2024
Description | Share | Value |
---|---|---|
Life Insurance | 100.0% | 8.9 kCr |
Total | 8.9 kCr |
Detailed comparison of Max Financial Services against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|---|
BAJAJFINSV | Bajaj FinservHolding Company | 3.27 LCr | 1.29 LCr | +5.25% | +23.55% | 19.34 | 2.53 | +26.78% | +13.75% |
SBILIFE | SBI Life Insurance Co.Life Insurance | - | - | +9.98% | +17.35% | - | - | - | - |
LICI | LIFE INSURANCE Corp OF INDIALife Insurance | - | - | +0.55% | -19.63% | - | - | - | - |
ICICIPRULI | ICICI Prudential Life Insurance Co.Life Insurance | - | - | +1.20% | +5.61% | - | - | - | - |
HDFCLIFE | HDFC LIFE INSURANCE Co.Life Insurance | - | - | +5.41% | +18.47% | - | - | - | - |
Investor Care | |
---|---|
Shares Dilution (1Y) | 0.00% |
Diluted EPS (TTM) | 7.29 |
Financial Health | |
---|---|
Debt/Equity | 0.00 |
Debt/Cashflow | 0.00 |
Valuation | |
---|---|
Market Cap | 43.71 kCr |
Price/Earnings (Trailing) | 138.74 |
Price/Sales (Trailing) | 0.89 |
EV/EBITDA | 106.34 |
Price/Free Cashflow | 7.02 |
MarketCap/EBT | 119.68 |
Fundamentals | |
---|---|
Revenue (TTM) | 49 kCr |
Rev. Growth (Yr) | -27.77% |
Rev. Growth (Qtr) | -33.26% |
Earnings (TTM) | 315.01 Cr |
Earnings Growth (Yr) | -59.23% |
Earnings Growth (Qtr) | -49.9% |
Profitability | |
---|---|
Operating Margin | 0.75% |
EBT Margin | 0.75% |
Return on Equity | 5.02% |
Return on Assets | 0.17% |
Free Cashflow Yield | 14.24% |